Protein abundance of class III beta-tubulin but not Δ2-alpha-tubulin or tau is related to paclitaxel response in carcinomas of unknown primary site

Anticancer Research

Volumn 28, Issue 2 B, 2008, Pages 1161-1167

  Sève, Pascal ^a,b,f   Reiman, Tony ^c   Isaac, Sylvie ^b   Trillet Lenoir, Véronique ^b,d   Lafanéchère, Laurence ^e   Sawyer, Michael ^c   Dumontet, Charles ^a,b  

^a UNIVERSITÉ LYON 1   (France)

^b HOSPICES CIVILS DE LYON   (France)

^c UNIVERSITY OF ALBERTA   (Canada)

^d EA 3738   (France)

^e INSERM   (France)

^f HÔTEL DIEU   (France)

Author keywords

Cancer of unknown primary site; Chemoresistance; CUP; Paclitaxel; Tau; Tubulin; Tubulin III

Indexed keywords

ALPHA TUBULIN; BETA TUBULIN; CARBOPLATIN; ETOPOSIDE; PACLITAXEL; TAU PROTEIN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER OF UNKNOWN PRIMARY SITE; COMPARATIVE STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICROTUBULES; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM METASTASIS; NEOPLASMS, UNKNOWN PRIMARY; PACLITAXEL; PROTEIN ISOFORMS; TAU PROTEINS; TREATMENT OUTCOME; TUBULIN;

EID: 42549102569     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Pavlidis N, Briasoulis E, Hainsworth J and Greco FA: Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer 39: 1990-2005, 2003.
2. Hainsworth JD and Greco FA: Treatment of patients with cancer of an unknown primary site. N Engl J Med 329: 257-263, 1993.
3. Seve P, Sawyer M, Hanson J, Broussolle C, Dumontet C, Mackey JR: The influence of comorbidities, age, and performance status on the prognosis and treatment of patients with metastatic carcinomas of unknown primary site: a population-based study. Cancer 106: 2058-2066, 2006.
4. Bugat R, Bataillard A, Lesimple T, Voigt JJ, Culine S, Lortholary A, Merrouche Y, Ganem G, Kaminsky MC, Negrier S, Perol M, Laforêt C, Bedossa P, Bertrand G, Coindre JM and Fizazi K: Summary of the Standards, Options and Recommendations for the management of patients with carcinoma of unknown primary site (2002). Br J Cancer 89(Suppl 1): S59-66, 2003.
5. NCCN practice guidelines for occult primary tumors. National Comprehensive Cancer Network. Oncology (Williston Park) 12: 226-309, 1998.
6. Hainsworth JD, Erland JB, Kalman LA, Schreeder MT and Greco FA: Carcinoma of unknown primary site: treatment with 1-hour paclitaxel, carboplatin, and extended-schedule etoposide. J Clin Oncol 15: 2385-2393, 1997.
7. Greco FA, Erland JB, Morrissey LH, Burris HA, 3rd, Hermann RC, Steis R, Thompson D, Gray J and Hainsworth JD: Carcinoma of unknown primary site: phase II trials with docetaxel plus cisplatin or carboplatin. Ann Oncol 11: 211-215, 2000.
8. Greco FA, Burris HA 3rd, Litchy S, Barton JH, Bradof JE, Richards P, Scullin DC Jr, Erland JB, Morrissey LH and Hainsworth JD: Gemcitabine, carboplatin, and paclitaxel for patients with carcinoma of unknown primary site: a Minnie Pearl Cancer Research Network study. J Clin Oncol 20: 1651-1656, 2002.
9. Briasoulis E, Kalofonos H, Bafaloukos D, Samantas E, Fountzilas G, Xiros N, Skarlos D, Christodoulou C, Kosmidis P and Pavlidis N: Carboplatin plus paclitaxel in unknown primary carcinoma: a phase II Hellenic Cooperative Oncology Group Study. J Clin Oncol 18: 3101-3107, 2000.
10. Dumontet C and Sikic BI: Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death. J Clin Oncol 17: 1061-1070, 1999.
11. Seve P and Dumontet C: Is beta-tubulin III a new predictive factor in patients receiving tubulin-binding agents? Lancet Oncol 9: 168-175, 2008.
12. Seve P, Mackey J, Isaac S, Tredan O, Souquet PJ, Pacheco Y, Lai R, Volch A and Dumontet C: Class III B-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel. Mol Cancer Therapeutics 4: 7001-7006, 2005.
13. Seve P, Reiman T, Lai R, Hanson J, Santos C, Johnson L, Dabbagh L, Sawyer M, Dumontet C and Mackey JR: Class III beta-tubulin is a marker of paclitaxel resistance in carcinomas of unknown primary site. Cancer Chemother Pharmacol 60: 27-34, 2007.
14. Seve P, Isaac S, Tredan O, Souquet PJ, Pacheco Y, Perol M, Lafanechere L, Penet A, Peiller EL and Dumontet C: Expression of class III {beta}-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy. Clin Cancer Res 11: 5481-5486, 2005.
15. Rouzier R, Rajan R, Wagner P, Hess KR, Gold DL, Stec J, Ayers M, Ross JS, Zhang P, Buchholz TA, Kuerer H, Green M, Arun B, Hortobagyi GN, Symmans F and Pustzai L: Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer. Proc Natl Acad Sci USA 102: 8315-8320, 2005.
16. Mimori K, Sadanaga N, Yoshikawa Y, Ishikawa K, Hashimoto M, Tanaka F, Sasaki A, Inoue H, Sugimachi K and Mori M: Reduced tau expression in gastric cancer can identify candidates for successful Paclitaxel treatment. Br J Cancer 94: 1894-1897, 2006.
17. Miller AB, Hoogstraten B, Staquet M and Winkler A: Reporting results of cancer treatment. Cancer 47: 207-214, 1981.
18. Kar S, Fan J, Smith MJ, Goedert M and Amos LA: Repeat motifs of tau bind to the insides of microtubules in the absence of taxol. Embo J 22: 70-77, 2003.
19. Le Chevalier T, Cvitkovic E, Caille P, Harvey J, Contesso G, Spielmann M and Rouesse J: Early metastatic cancer of unknown primary origin at presentation. A clinical study of 302 consecutive autopsied patients. Arch Intern Med 148: 2035-2039, 1988.
20. Paturle-Lafanechere L, Manier M, Trigault N, Pirollet F, Mazarguil H and Job D: Accumulation of delta 2-tubulin, a major tubulin variant that cannot be tyrosinated, in neuronal tissues and in stable microtubule assemblies. J Cell Sci 107: 1529-1543, 1994.
21. Burkhart CA, Kavallaris M and Horwitz SB: The role of β-tubulin isotypes in resistance to antimitotic drugs. Biochim Biophys Acta 1471: 1-9, 2001.
22. Kavallaris M, Kuo DY, Burkhart CA, Regl DL, Norris MD, Haber M and Horwitz SB: Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. J Clin Invest 100: 1282-1293, 1997.
23. Ranganathan S, Benetatos CA, Colarusso PJ, Dexter DW and Hudes GR: Altered beta-tubulin isotype expression in paclitaxel-resistant human prostate carcinoma cells. Br J Cancer 77: 562-566, 1998.
24. Liu B, Staren ED, Iwamura T, Appert HE and Howard JM: Mechanisms of taxotere-related drug resistance in pancreatic carcinoma. J Surg Res 99: 179-186, 2001.
25. Giannakakou P, Sackett DL, Kang YK, Zhan Z, Buters JT, Fojo T and Poruchynsky MS: Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem 272: 17118-17125, 1997.
26. Lu Q and Luduena RF: Removal of beta III isotype enhances taxol induced microtubule assembly. Cell Struct Funct 18: 173-182, 1993.
27. Banerjee A, Roach MC, Trcka P and Luduena RF: Increased microtubule assembly in bovine brain tubulin lacking the type III isotype of beta-tubulin. J Biol Chem 265: 1794-1799, 1990.
28. Derry WB, Wilson L, Khan IA, Luduena RF and Jordan MA: Taxol differentially modulates the dynamics of microtubules assembled from unfractionated and purified beta-tubulin isotypes. Biochemistry 36: 3554-3562, 1997.
29. Hari M, Yang H, Zeng C, Canizales M and Cabral F: Expression of class III beta-tubulin reduces microtubule assembly and confers resistance to paclitaxel. Cell Motil Cytoskeleton 56: 45-56, 2003.
30. Kavallaris M, Burkhart CA and Horwitz SB: Antisense oligonucleotides to class III beta-tubulin sensitize drug-resistant cells to Taxol. Br J Cancer 80: 1020-1025, 1999.
31. Gan PP, Pasquier E and Kavallaris M: Class III beta-tubulin mediates sensitivity to chemotherapeutic drugs in non small cell lung cancer. Cancer Res 67: 9356-9363, 2007.
32. Kamath K, Wilson L, Cabral F and Jordan MA: beta III-tubulin induces paclitaxel resistance in association with reduced effects on microtubule dynamic instability. J Biol Chem 280: 12902-12907, 2005.
33. Rosell R, Scagliotti G, Danenberg KD, Lord RV, Bepler G, Novello S, Cooc J, Crino L, Sanchez JJ, Taron M et al: Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer. Oncogene 22: 3548-3553, 2003.
34. Seve P, Lai R, Ding K, Winton T, Butts C, Mackey J, Dumontet C, Dabbagh L, Aviel-Ronen S, Seymour L, Whitehead M, Tsao MS, Shepherd FA and Reiman T: Class III beta-tubulin expression and benefit from adjuvant cisplatin/ vinorelbine chemotherapy in operable non-small cell lung cancer: analysis of NCIC JBR.10. Clin Cancer Res 13: 994-999, 2007.